Synthesis of Fluorinated and Nonfluorinated Tebufenpyrad Analogues for the Study of Anti-angiogenesis MOA
Open Access
- 17 June 2014
- journal article
- review article
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 18 (8) , 1027-1036
Abstract
In this contribution we report the synthesis of fluorinated and nonfluorinated tebufenpyrad analogues to explore potential druglike properties through the phenotypic screening as part of the Lilly Open Innovation Drug Discovery (OIDD) program.Keywords
This publication has 18 references indexed in Scilit:
- From 2000 to Mid-2010: A Fruitful Decade for the Synthesis of PyrazolesChemical Reviews, 2011
- Recent Advances in the Synthesis of Pyrazoles. A ReviewOrganic Preparations and Procedures International, 2009
- Synthesis of New Fluorinated Tebufenpyrad Analogs with Acaricidal Activity Through Regioselective Pyrazole FormationThe Journal of Organic Chemistry, 2008
- Improved Regioselectivity in Pyrazole Formation through the Use of Fluorinated Alcohols as Solvents: Synthesis and Biological Activity of Fluorinated Tebufenpyrad AnalogsThe Journal of Organic Chemistry, 2008
- Non-nucleoside inhibitors of the measles virus RNA-dependent RNA polymerase complex activity: Synthesis and in vitro evaluationBioorganic & Medicinal Chemistry Letters, 2007
- Pyrazole-based factor Xa inhibitors containing N-arylpiperidinyl P4 residuesBioorganic & Medicinal Chemistry Letters, 2007
- Sublethal Effects of Tebufenpyrad on the Eggs and Immatures of Two-Spotted Spider Mite, Tetranychus urticaeExperimental and Applied Acarology, 2005
- Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3- (trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib)Journal of Medicinal Chemistry, 1997
- Sildenafil, a novel effective oral therapy for male erectile dysfunctionBritish Journal of Urology, 1996
- Biochemical and pharmacological characterisatioN OF SR141716A, the first potent and selective brain cannabinoid receptor antagonistLife Sciences, 1995